Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CGTX | US
-0.02
-4.59%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.47
0.51
0.51
0.47
Cognition Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812 an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
81.9%1 month
104.4%3 months
135.3%6 months
114.2%-
-
0.86
0.03
0.02
-0.44
-
-
-58.61M
18.93M
18.93M
-
-
-
-
-108.31
1.04
1.91
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.19
Range1M
0.21
Range3M
2.19
Rel. volume
0.29
Price X volume
84.35K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sensei Biotherapeutics Inc | SNSE | Biotechnology | 0.78 | 19.62M | 88.82% | n/a | 9.67% |
| GeoVax Labs Inc | GOVX | Biotechnology | 2.24 | 19.10M | 5.66% | n/a | -6.03% |
| Matinas BioPharma Holdings Inc | MTNB | Biotechnology | 3.73 | 18.71M | -9.47% | n/a | 16.97% |
| Kazia Therapeutics Limited | KZIA | Biotechnology | 0.5616 | 18.69M | 11.78% | n/a | 6.82% |
| Sol-Gel Technologies Ltd | SLGL | Biotechnology | 0.67 | 18.66M | -3.25% | n/a | 3.99% |
| MONOPAR THERAPEUTICS | MNPR | Biotechnology | 5.25 | 18.48M | -4.55% | n/a | 0.00% |
| Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 15.24 | 18.02M | -11.70% | n/a | 0.22% |
| Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.93 | 17.86M | 2.09% | n/a | 0.00% |
| Minerva Neurosciences Inc | NERV | Biotechnology | 2.545 | 17.80M | 1.39% | n/a | -194.60% |
| Athira Pharma Inc | ATHA | Biotechnology | 0.4571 | 17.57M | -3.26% | n/a | 1.69% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.44 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.86 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 135.33 | - | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 18.93M | - | Emerging |